Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | UCB6114 |
Synonyms | |
Therapy Description |
UCB6114 is a monoclonal antibody that binds to Gremlin-1, resulting in activation of BMP and potentially leading to anti-tumor activity (Journal of Clinical Oncology 2022 40:4_suppl, TPS221). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
UCB6114 | UCB 6114|UCB-6114|Ginisortamab | UCB6114 is a monoclonal antibody that binds to Gremlin-1, resulting in activation of BMP and potentially leading to anti-tumor activity (Journal of Clinical Oncology 2022 40:4_suppl, TPS221). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |